{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.46","upperLimit":"24.41","value":"14.1"},{"comment":"Not reached","groupId":"OG001","lowerLimit":"11.17","upperLimit":"NA","value":"16.8"},{"groupId":"OG002","lowerLimit":"8.97","upperLimit":"36.04","value":"14.7"},{"groupId":"OG003","lowerLimit":"7.23","upperLimit":"11.14","value":"8.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"315"},{"groupId":"OG001","value":"291"},{"groupId":"OG002","value":"127"},{"groupId":"OG003","value":"314"}],"units":"Participants"}],"description":"EORTC 18-item hepatocellular cancer health-related quality of life questionnaire (QLQ-HCC18) is an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30, which includes 8 symptom scales such as fatigue, jaundice, body image, nutrition, pain, fever, sex life and abdominal swelling. A high score for a symptom scale/item represents a high level of symptomatology/problem. A clinically meaningful deterioration is defined as an increase in the score from baseline of ≥10. Time to deterioration is defined as the time from the date of randomization until the date of the first clinically meaningful deterioration that is confirmed at a subsequent visit or death by any cause in the absence of a clinically meaningful deterioration, regardless of whether the patient discontinues study drug(s) or receives another anticancer therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Durvalumab 1500 mg every 4 weeks (Q4W)","id":"OG000","title":"Durva 1500 mg"},{"description":"Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W","id":"OG001","title":"Treme 300 mg x1 Dose + Durva 1500 mg"},{"description":"Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W","id":"OG002","title":"Treme 75 mg x4 Doses + Durva 1500 mg"},{"description":"Sorafenib 400 mg twice daily (BID)","id":"OG003","title":"Sora 400 mg"}],"paramType":"MEDIAN","populationDescription":"A subset of the FAS who have a baseline symptom score \\<= 90. T75+D arm was closed during study.","reportingStatus":"POSTED","timeFrame":"At baseline and every 8 weeks for the first 48 weeks and then every 12 weeks thereafter until death or the final analysis DCO (27Aug2021), assessed up to approximately 46 months.","title":"EORTC QLQ-HCC18 Time to Symptom (Abdominal Pain) Deterioration","type":"SECONDARY","unitOfMeasure":"months"}